Wikipedia:Articles for deletion/Proximagen


 * The following discussion is an archived debate of the proposed deletion of the article below. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review).  No further edits should be made to this page.

The result was   redirect to Upsher-Smith Laboratories. Spartaz Humbug! 17:25, 1 July 2013 (UTC)

Proximagen

 * – ( View AfD View log  Stats )

Non notable company with no approved drugs   DGG ( talk ) 04:44, 22 June 2013 (UTC)
 * Note: This debate has been included in the list of United Kingdom-related deletion discussions. • Gene93k (talk) 15:45, 22 June 2013 (UTC)
 * Note: This debate has been included in the list of Business-related deletion discussions. • Gene93k (talk) 15:45, 22 June 2013 (UTC)
 * Note: This debate has been included in the list of Medicine-related deletion discussions. • Gene93k (talk) 15:45, 22 June 2013 (UTC)


 * Merge/Redirect to Upsher-Smith Laboratories, of which it is a wholly owned subsidiary. --MelanieN (talk) 17:01, 22 June 2013 (UTC)
 * I added a sentence about Proximagen to the Upsher-Smith article. --MelanieN (talk) 17:10, 22 June 2013 (UTC)


 * Keep or full merge -- The article states that it is an AIM-listed company. As such it should be notable.  The fact that it has been taken over by an American company, which will presumably continue to run the Cambridge research laboratroies seems no reason to delete it.  If it was notable befeore the takeover (and I am certain that it was), the takeover should make no difference.  Notability in WP terms should not be temporary.  Peterkingiron (talk) 16:25, 23 June 2013 (UTC)
 * The above discussion is preserved as an archive of the debate. Please do not modify it. Subsequent comments should be made on the appropriate discussion page (such as the article's talk page or in a deletion review). No further edits should be made to this page.